The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4; 14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.

The present disclosure relates to a composition for treating or diagnosing osteoarthritis targeting activin A receptor type 2B (ACVR2B). More specifically, the present disclosure provides ACVR2B as a biomarker for diagnosing osteoarthritis because it was found that expression and activity of ACVR2B were increased at an early stage of osteoarthritis, expression of Mmp3, Mmp13, and Cox2 that induce destruction of cartilage was increased thereby, and expression of the genes was suppressed by inhibition of ACVR2B expression. In addition, since it was found that osteoarthritis was alleviated by suppressing the expression of ACVR2B, the present disclosure provides an ACVR2B expression or activity inhibitor as a therapeutic agent for osteoarthritis.

The present disclosure relates to a composition for treating or diagnosing osteoarthritis targeting activin A receptor type 2B (ACVR2B). More specifically, the present disclosure provides ACVR2B as a biomarker for diagnosing osteoarthritis because it was found that expression and activity of ACVR2B were increased at an early stage of osteoarthritis, expression of Mmp3, Mmp13, and Cox2 that induce destruction of cartilage was increased thereby, and expression of the genes was suppressed by inhibition of ACVR2B expression. In addition, since it was found that osteoarthritis was alleviated by suppressing the expression of ACVR2B, the present disclosure provides an ACVR2B expression or activity inhibitor as a therapeutic agent for osteoarthritis.

Described are compounds and compositions for transdifferentiation of glioblastoma cells to antigen presenting cells. Methods of using the compounds and compositions to treat glioblastoma and to induce an immune response against a glioblastoma are also described.

Described are compounds and compositions for transdifferentiation of glioblastoma cells to antigen presenting cells. Methods of using the compounds and compositions to treat glioblastoma and to induce an immune response against a glioblastoma are also described.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided are antibodies, and fragments and derivatives thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor. Also provided are nanoparticle conjugates of the antibodies and fragments and derivatives thereof, particularly humanized derivatives thereof, compositions and delivery agents that include the same, host cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.

Provided are antibodies, and fragments and derivatives thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor. Also provided are nanoparticle conjugates of the antibodies and fragments and derivatives thereof, particularly humanized derivatives thereof, compositions and delivery agents that include the same, host cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.

The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.